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Background: Hepatocellular carcinoma (HCC) is a common and aggressive cancer, and the treatment options are
limited for patients with advanced HCC. Bufalin, the major digoxin-like component of the traditional Chinese
medicine Chansu, exhibits significant anti-tumor activities in many tumor cell lines. In the present study, we
investigated the effect of bufalin on the inhibition of an AKT-related signaling pathway, and examined the
relationship between regulatory proteins and anti-tumor effects in hepatoma cells.
Methods: Proliferation, wound healing, transwell-migration/invasion and adhesion assays were performed in
HCCLM3 and HepG2 cell lines. The protein levels of pAKT, AKT, pGSK3β, GSK3β, pβ-catenin, β-catenin, E-cadherin,
MMP-9, and MMP-2 were measured by western blot analysis. E-Cadherin and β-catenin expression levels were also
evaluated by immunofluorescence.
Results: Bufalin inhibited hepatoma cell proliferation, migration, invasion and adhesion. In addition, treatment with
bufalin significantly decreased the levels of pAKT, pGSK3β, MMP-9, and MMP-2, while increasing the levels of GSK3β
and E-cadherin and suppressing the nuclear translocation of β-catenin.
Conclusions: Bufalin is a potential anti-HCC therapeutic candidate through its inhibition of the AKT/GSK3β/β-catenin/
E-cadherin signaling pathway. Further studies with bufalin are warranted in patients with HCC, especially those with the
disease at advanced stages.
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Hepatocellular carcinoma (HCC) is one of the main
causes of cancer mortality in many countries, especially
in East and Southeast Asia and Central and West Africa
[1]. HCC is the fifth most common cancer in men and
the seventh most common in women, and is the third
leading cause of cancer death [2]. The disease is usually
diagnosed at an advanced stage and recurrence rates are
very high; approximately 30–40% within 5 years. Patients
with advanced HCC have a median survival of about 6–
8 months, and there are limited effects in the treatment
for these patients [3]. 5-Fluorouracil and mitomycin-C,
widely used chemotherapeutic drugs, have limited overall* Correspondence: yang.yunke@zs-hospital.sh.cn
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reproduction in any medium, provided the oreffects in the treatment of HCC owing to resistance.
Nowadays, patients with advanced HCC are treated with a
comprehensive series of vascular interventional therapy,
but their median life spans are not obviously prolonged
[4]. Certain Chinese traditional medicines were found to
be effective in treatment on cancers, drugs like Songyou
Yin which were reported to improve the efficacy of
chemotherapy in HCC [5]. Therefore, novel therapeutic
strategies are essential to improve the clinical manage-
ment of patients with HCC.
Bufalin, the major digoxin-like component of the trad-
itional Chinese medicine Chansu, is an extract from the
skin and parotid venom glands of Bufo bufo gargarizans
cantor [6]. Chansu, initially recorded more than 1000 years
ago, is a well-known traditional Chinese medicine widely
used in clinical cancer therapy in China [7,8]. Recent
experimental studies have suggested that Chansu and its. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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via the inhibition of cell proliferation, induction of cell
differentiation and apoptosis, disruption of the cell cycle,
inhibition of angiogenesis, reversal of multidrug resistance,
and regulation of the immune response [9]. In a previous
study, it was demonstrated that bufalin caused apoptosis
of gastric cancer cells by inhibition of the AKT signaling
pathway via CBL-B and CBL-C [10]. AKT (also known
as PKB) is a master regulator that when activated by
phosphorylation modifies at least 10 major regulatory pro-
teins and initiates many pathways in tumor cells [11].
PI3K/AKT signaling is involved in the regulation of cancer
cell proliferation, motility, survival and metabolism
[12,13]. AKT is also instrumental in angiogenesis and
epithelial mesenchymal transitions during tumorigen-
esis [13,14].
The purpose of this study was to observe the anti-
tumor effects and molecular mechanisms of bufalin in
hepatoma cells, especially the AKT signaling pathway.Figure 1 The chemical structure of bufalin.Methods
Cell lines
The human hepatoma cell lines HCCLM3 and HepG2
were provided by the Liver Cancer Institution, Zhongshan
Hospital, Fudan University (Shanghai, China) and were
used in all experiments. Both cell lines were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS) at 37°C
in a humidified atmosphere of 5% CO2 and 95% air.Compounds and antibodies
Bufalin (purity >98%) was purchased from Shanghai
Tauto Biotech Co., Ltd. (Shanghai, China), dissolved in
ethanol at a concentration of 10–2 mol/L, sterilized
with a 0.22-μm filter (Millipore, Billerica, MA, USA),
and stored at 4°C. Figure 1 shows the chemical structure
of bufalin. Antibodies against GSK3β, pGSK3β (Ser 9),
β-catenin, pβ-catenin (Ser 33/37), GAPDH, and E-
cadherin were purchased from Epitomics Inc. (Burlin-
game, CA, USA). Antibodies against AKT, pAKT (Ser
473), MMP-2, MMP-9, and inhibitor LY294002 were
purchased from Cell Signaling Technology Inc. (Beverly,
MA, USA).Cell proliferation assay
HCCLM3 or HepG2 cells (1 × 104) were plated into 96-
well plates in triplicate and then treated with the indi-
cated concentrations of bufalin. Cell proliferation was
assessed after 48 h using CCK-8 (Dojindo, Tokyo, Japan)
according to the manufacturer’s instructions. Results are
expressed as the absorbance of each well at 450 nm
(OD = 450).Wound healing assay
To determine cell motility, HCCLM3 and HepG2 cells
were seeded separately into 24-well flat-bottomed plates
and grown to 90% confluence. After aspirating the me-
dium, the monolayer was scraped with a sterile mi-
cropipette tip to create a denuded zone with a constant
width. The cells were then washed with phosphate-
buffered saline (PBS) twice and exposed to the indicated
concentrations of bufalin (0, 1, 10, or 100 nmol/L). The
distances of wounds were monitored and photographed
at 0, 24, and 48 h after treatment. Cell motility was
calculated by the following formula: Cell motility = (dis-
tance at 24 or 48 h – distance at 0 h) / distance at 0 h.
Transwell-migration/invasion assay
Cell migration was analyzed in a Transwell permeable
support system (Corning Inc., Corning, NY, USA) con-
taining 24-well transwell (unit 8 μm pore size poly-
vinylidene fluoride) filters. HCCLM3 and HepG2 were
pretreated with 0, 1, 10, or 100 nmol/L bufalin for 48 h
and then seeded into the upper insert at densities of 1 ×
105 cells/24-well for HCCLM3 and 5 × 104 cells/24-well
for HepG2 in serum-free DMEM. DMEM containing
10% FBS was added to the lower chamber as a chemo-
attractant. After culturing for 48 h, non-invading cells
were removed from the upper surface by wiping with a
cotton swab. The membrane was fixed with 4% formal-
dehyde for 15 min at room temperature. The invading
cells were stained with Giemsa (Sigma, Munich, Germany)
for 25 min, and their numbers in five fields of each tripli-
cate filter were counted using an inverted microscope.
The cell invasion assay was carried out similarly, except
Figure 2 Inhibition curves of bufalin on hepatoma cell
proliferation. Proliferation of HCCLM3 and HepG2 cells was
significantly inhibited by bufalin in a dose-dependent manner,
especially when exposed to more than 10 nmol/L. All data represent
the mean ± SD (n = 3).
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Franklin Lakes, NJ, USA) was added to each well 6 h
before cells were seeded onto the membrane.
Cell adhesion assay
The 96-well flat-bottomed plates were precoated with
50 μl/well of 1:8 PBS-diluted Matrigel at 4°C overnight.
After removing all coating solutions, the plates were
blocked with 150 μl/well of 1% bovine serum albumin
for 1 h at 37°C. Then HCCLM3 and HepG2 cells that
had been treated with 0, 1, 10, or 100 nmol/L bufalin for
24 h were seeded into the Matrigel-coated wells at 1 ×
105 cells/well in triplicate and incubated for 4 h at 37°C
in 5% CO2. After extensive washing, cells were fixed
with 4% formaldehyde (100 μl/well) for 15 min and
stained with a hematoxylin solution for 10 min. The
average numbers of adhered cells in five fields were
counted using an inverted microscope.
Western blot analysis
The total and phosphorylated levels of AKT, GSK3β, and
β-catenin and the protein levels of E-cadherin, MMP-9,
and MMP-2 were evaluated by western blotting. Cells
treated with bufalin were washed with ice-cold PBS and
extracted in protein lysis buffer (Pierce, Rockford, IL,
USA). Protein concentrations were determined with the
BCA Protein Assay Kit (Beyotime, Shanghai, China).
Protein samples of cell lysates were mixed with 5×
sodium dodecyl sulfate (SDS) loading buffer (1:4), boiled
for 5 min, and then separated on 8–10% SDS polyacryl-
amide gels. After electrophoresis, proteins were trans-
ferred onto polyvinylidene fluoride membranes, blocked
in 5% nonfat dry milk in Phosphate Buffered Saline with
Tween-20 (PBST) for 1 h, and incubated with corre-
sponding rabbit monoclonal antibodies against pAKT
(dilution 1:1000) and AKT (1:1000), pGSK3β (1:10000)
and GSK3β (1:5000), pβ-catenin (1:500) and β-catenin
(1:5000), E-cadherin (1:5000), MMP-2 (1:1000), MMP-9
(1:1000), and GAPDH (1:1000) overnight at 4°C. The
membranes were washed three times with PBST and
incubated for 1 h with a peroxidase conjugated second-
ary antibody. After washing again three times with PBST,
blots were incubated with chemiluminescence substrate
(ECL plus, Beyotime Inc., Shanghai, China), and digital
images were acquired using a Chemi-Doc system em-
ploying Quantity One software (Bio-Rad Laboratories
Inc., Hercules, CA, USA). Three independent blots
were performed for each protein.
Immunofluorescence
The expression levels of β-catenin and E-cadherin in
bufalin-treated HCCLM3 and HepG2 cells were also
evaluated by immunofluorescence. Cells were grown on
glass cover slips to 60–80% confluence, and then fixed,permeabilized, and blocked. Cells were then incubated
with primary rabbit monoclonal against E-cadherin and
β-catenin overnight at 4°C. The next day, slides were
washed and incubated with anti-rabbit fluorescein
isothiocyanate-conjugated secondary antibody (Jackson,
Lancaster, PA, USA). Cells were counterstained with
4′-6-diamidino-2-phenylindole to visualize cell nuclei and
imaged by fluorescence microscopy (Olympus, Tokyo,
Japan).
Statistical analyses
Statistical analyses were performed with SPSS 17.0 for
Windows (SPSS, Chicago, IL, USA). Quantitative vari-
ables are expressed as mean ± SD and were analyzed by
analysis of variance. Results were considered statistically
significant at P < 0.05.
Results
Inhibitory effects of bufalin on hepatoma
cell proliferation
To explore the effects of bufalin on hepatoma cell pro-
liferation, HCCLM3 and HepG2 cells were treated with
bufalin at doses ranging from 0 to 100,000 nmol/L.
Bufalin dramatically decreased the proliferation of the
two tested cell lines in a dose-dependent manner, espe-
cially when exposed to more than 10 nmol/L (Figure 2).
The inhibitory ratio of bufalin on cell proliferation was
significantly increased from 21.4% ± 2.4% to 87.1% ± 0.7%
in HCCLM3 cells and from 35% ± 5% to 88.6% ± 1.6%
in HepG2 cells after a 48-h treatment. The data suggest
that bufalin has robust suppressive effects on hepatoma
cell proliferation.
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To examine the effects of bufalin on cell migration, we
performed wound healing and transwell-migration as-
says using the same two hepatoma cell lines. All wound
healing images representing cell migration capabilities
were taken at the same magnification and time after
bufalin treatments. At 48 h, the wound was healed
approximately 65.8% ± 4.8% in HCCLM3 and 84.0% ± 5%
in HepG2. Bufalin significantly reduced cell motility in
both HCCLM3 and HepG2 compared with the control
(Figure 3). After treatment of HCCLM3 and HepG2 with
bufalin at 100 nmol/L for 48 h, only 23.6% ± 4.6% and
41.6% ± 1.4% of cells had migrated, respectively. The mi-
gration assay using the transwell-migration system also
demonstrated that bufalin (10 and 100 nmol/L) effect-
ively inhibited cell migration of HCCLM3 and HepG2
(Figure 4). Furthermore, a transwell-invasion assay was
used to determine the invasive activity of tumor cells
across the basement membrane. Our results revealed
that bufalin significantly decreased the invasive potential
of HCCLM3 and HepG2 in a dose-dependent manner
(Figure 5).
Effect of bufalin on hepatoma cell adhesion
To investigate the effect of bufalin on cell adhesion to
the extracellular matrix, adhesion assays using HCCLM3
and HepG2 cells were performed in the presence orFigure 3 Effects of bufalin on wound healing ability of hepatoma cell
(B, D) were allowed to proliferate for another 24 and 48 h in the absence o
the mean of three individual experiments performed in triplicate; error barsabsence of bufalin. Pre-incubation of hepatoma cells
with bufalin (10 and 100 nmol/L) markedly inhibited the
adhesion of HCCLM3 and HepG2 (Figure 6).
Effect of bufalin on the expression of AKT in
hepatoma cells
The PI3K/AKT signaling pathway is one of the most
important cellular pathways regulating HCC progression
and affects cell proliferation, motility, and survival [12,13].
Therefore, we investigated whether bufalin was able to
modulate the protein expression of AKT and pAKT
(Ser 473) in human hepatoma cells by western blot
analysis. At a dose of 100 nmol/L, bufalin significantly
downregulated the expression of pAKT in both HCCLM3
and HepG2 cells without affecting the total protein
levels of AKT (Figure 7). LY294002, a potent inhibitor
of AKT, also reduced the levels of pAKT in both hepa-
toma cell lines. Furthermore, bufalin inhibited the expres-
sion of pAKT in HCCLM3 in a time-dependent manner.
Our results clearly indicate that bufalin can significantly
inhibit the activities of AKT in human hepatoma cells.
Effects of bufalin on GSK3β and β-catenin expression
and β-catenin nuclear translocation in hepatoma cells
To further examine the molecular actions of bufalin, we
investigated the downstream molecules of the PI3K/
AKT signaling pathway after bufalin treatment. Bufalins. After scratches were made, HCCLM3 cells (A, C) and HepG2 cells
r presence of different concentrations of bufalin. Columns represent
represent SD. *P < 0.05, **P < 0.01, vs. controls.
Figure 4 Effects of bufalin on the migratory ability of hepatoma cells. Cell migration of HCCLM3 (A, C) and HepG2 (B, D) after treatment
with indicated concentrations of bufalin for 48 h. Columns represent the mean of three individual experiments performed in triplicate; error bars
represent SD. **P < 0.01, vs. controls.
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protein (Ser 9) and increased GSK3β protein activation
(Figure 8A, C). Activation of GSK3β induces ubiquitin-
dependent degradation of β-catenin, which acts as an
important regulator of cell motility, invasion, and adhesion
[15]. Therefore, we investigated the effects of bufalin on
the downstream molecule levels in hepatoma cells. How-
ever, no pβ-catenin was detected in bufalin-treated cells
(data not shown), and no obvious changes were found in
the protein levels of β-catenin (Figure 8B, D). According
to an immunofluorescence assay, bufalin suppressed the
nuclear translocation of β-catenin both in HCCLM3 and
HepG2 cells, especially in the latter (Figure 8E, F). In
addition, our results demonstrated that treatment with
LY294002 also suppressed the nuclear translocation of β-
catenin in the two cell lines. These results confirm that
bufalin inhibited Wnt signaling by decreasing the nuclear
translocation of β-catenin.Effects of bufalin on E-cadherin, MMP2, and MMP9
expression in hepatoma cells
Nuclear localization of β-catenin promotes the expres-
sion of E-cadherin-mediated cell adhesion, sequentially
endows tumor cells with migratory and invasion proper-
ties, and contributes to metastasis [15]. Therefore, we
further investigated the downstream molecular actions
of E-cadherin after the inhibitory nuclear translocation
of β-catenin. First, E-cadherin protein expression was
investigated by western blotting after treatment with
bufalin for 48 h at a dose of 100 nmol/L. We found that
bufalin significantly increased E-cadherin expression in
HCCLM3 and HepG2 cells. These results were also
confirmed by an immunofluorescence assay (Figure 9A–
D). Overexpression of E-cadherin in highly invasive cells
may reduce tumor cell invasiveness by decreasing MMP-
9 and MMP-2 expression [16,17]. Therefore, the protein
expression levels of MMP-2 and MMP-9 were investi-
Figure 5 Effects of bufalin on the invasive ability of hepatoma cells. Cell invasion of HCCLM3 (A, C) and HepG2 (B, D) after treatment with
indicated concentrations of bufalin for 48 h. Columns represent the mean of three individual experiments performed in triplicate; error bars
represent SD.**P < 0.01, vs. controls.
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(100 nmol/L) or LY294002 (10 μmol/L). Indeed, bufalin
significantly decreased MMP-9 expression in HCCLM3
and HepG2 cells and MMP-2 expression in HepG2 cells.
These results suggest that bufalin can regulate the ex-
pression of MMP-9 and MMP-2 at the transcriptional
level in hepatoma cells.
Discussion
Although 90% of cancer deaths are caused by metastasis,
the pathogenesis and mechanisms underlying this event
remain poorly defined [18]. Recent studies suggested
that the epithelial to mesenchymal transition initiates
cancer cell dissemination, inducing non-cancer stem
cells to enter into a cancer stem cell-like state [19], and
promotes metastatic seeding accompanying the down
regulation of E-cadherin [20,21]. The activation of the
PI3K/AKT signaling pathway is emerging as a central
feature of the epithelial to mesenchymal transition [14].
AKT, which is downstream of PI3K, has been shownto suppress transcription of the E-cadherin gene. Hy-
peractivated AKT decreases cell–cell connections by
phosphorylating GSK3β (Ser 9), which is followed by
ubiquitination and degradation, and the elimination of
GSK3β permits β-catenin to accumulate and localize in
the nucleus [11]. β-catenin is an essential molecule in the
canonical Wnt signaling pathway. Its nuclear stabilization
inhibits the expression of E-cadherin and promotes
mesenchymal phenotype maintenance, migration, and
invasion of carcinoma cells [15]. A current literature
review shows the importance of cross-talk between the
PI3K/AKT and β-catenin pathways as a therapeutic target
in treatment of malignant tumors [22].
The traditional Chinese medicine Chansu, which is
obtained from the skin and parotid venom glands of
toads, has been used as a therapeutic reagent for several
malignant tumors, including HCC, non-small cell lung
cancer, and pancreatic cancer in China [7]. In a pilot
study of treatment with Chansu extracts, 40% of ad-
vanced cancers (6/15) had prolonged disease stability or
Figure 6 Effects of bufalin on the cell adhesion ability of hepatoma cells. Adhesion of HCCLM3 (A, C) and HepG2 (B, D) cells to Matrigel
were markedly inhibited by bufalin at doses of 10 nmol/L and 100 nmol/L as compared with control group cells. **P < 0.01, vs. controls.
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digoxin-like active component of Chansu, exhibits a variety
of biological activities, including cardiotonic, anesthetic,
blood pressure stimulatory, respiratory, and anti-neoplastic
effects [23]. These unwanted side-effects may preventFigure 7 Effects of bufalin on AKT and pAKT (Ser 473) expression in h
bufalin (100 nmol/L) and LY294002 (10 mmol/L) for the indicated times. GA
expression of AKT and pAKT (Ser 473). Columns represent the mean of thre
SD; LY represent LY294002. **P < 0.01, vs. controls.its use in cancer treatment. The potential use of cardiac
glycoside-like compounds for the treatment of cancer,
initially investigated 40 years ago, was abandoned be-
cause of the toxicity of these compounds. However, in
1999, a Scandinavian oncologist suggested that tumorepatoma cells. (A) HCCLM3 and HepG2 cells were treated with
PDH was used as a loading control. (B) Quantitative analysis of
e individual experiments performed in triplicate; error bars represent
Figure 8 Effects of bufalin on GSK3β, β-catenin levels, and nuclear translocation of β-catenin. Protein levels of pGSK3β (A, C) and
β-catenin (B, D) were analyzed by western blotting in bufalin-treated (100 nmol/L) hepatoma cells. LY294002 (10 μmol/L) was included as a
positive control. GAPDH was used as a loading control. Nuclear translocation of β-catenin in bufalin- and LY29400-treated hepatoma cells (E, F)
was monitored by immunofluorescence assay. Columns represent the mean of three individual experiments performed in triplicate; error bars
represent SD; LY represent LY294002. **P < 0.01, vs. controls.
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without toxicity in humans [24]. Therefore, these agents
might be useful for the treatment of cancer.
Activation of the PI3K/AKT signaling pathway con-
tributes to cell proliferation, survival, motility, and angio-
genesis, processes that are responsible for tumorigenesis,
invasion, and metastasis [25]. For this reason, many
pharmaceutical companies and academic laboratories are
actively developing inhibitors targeting PI3K, AKT, and
other important components in this pathway. Recently,lipid-soluble cardiac glycosides such as bufalin and
oleandrin have been suggested as potent agents that
might be useful as AKT inhibitors [26,27]. Because
bufalin was reported to play an inhibitory role on AKT
phosphorylation in gastric cancer cells [10], we hypoth-
esized that a similar biological function may also exist
in hepatoma cells. Our research here demonstrated that
bufalin inhibited the phosphorylation of AKT, which in
turn inhibited cell proliferation, migration, and invasion
in the two hepatoma cell lines, and revealed that
Figure 9 Effects of bufalin on expression of E-cadherin, MMP-9, and MMP-2 in hepatoma cells. The protein levels of E-cadherin (A, B) and
MMP-9 and MMP-2 (E, F) were analyzed by western blotting in HCCLM3 and HepG2 cells after exposure to bufalin (100 nmol/L) and LY294002
(10 μmol/L). GAPDH was used as a loading control. Immunofluorescence assay showed expression of E-cadherin after exposure to bufalin and
LY294002 in the two hepatoma cell lines (C, D). Columns represent the mean of three individual experiments performed in triplicate; error bars
represent SD; LY represent LY294002. *P < 0.05, *P < 0.01, vs. controls.
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GSK3β (Ser 9) and increase the activated form of GSK3β.
Although no obvious changes were found in the protein
levels of β-catenin, the nuclear accumulation of β-catenin
was markedly blocked in the two hepatoma cell lines.
In turn, the reduced nuclear accumulation of β-catenin
significantly increased the transcription of the trans-
membrane protein E-cadherin. In addition, bufalin was
also able to decrease MMP-2 expression, especially inHepG2 cells, and MMP-9 in both cell lines. These results
confirm the previous observations that overexpression
of E-cadherin in human prostate cancer and mouse skin
cancer reduced tumor cell invasiveness by decreasing
MMP-2 and MMP-9 expression levels [16,17]. Therefore,
upregulation of E-cadherin and a concomitant reduction
in MMP-2/MMP-9 might negatively regulate cell prolifer-
ation, cell invasiveness, cell adhesion of HCCLM3 and
HepG2. Similar results were observed in both of these
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AKT/GSK3β/β-catenin/E-cadherin signaling in HCC.
In brief, our results suggest that AKT is the main regu-
latory protein of the AKT/GSK3β/β-catenin/E-cadherin
signaling pathway, which regulates the expression and
phosphorylation of GSK3β and the nuclear translocation
of β-catenin. β-Catenin functions as a negative regulation
of the downstream molecule E-cadherin, which modifies
the expression of downstream target proteins MMP2,
MMP9.
This signaling pathway activation and protein regula-
tion are related to hepatoma cell proliferation, migration,
invasion, and adhesion. Thus, bufalin exhibits multiple
anti-tumor effects on hepatoma cells because the me-
chanisms underlying bufalin action appears to mediate
AKT/GSK3β/β-catenin/E-cadherin signaling and affect
regulation of protein expression.
Conclusion
In summary, our results suggest that bufalin exhibits
multiple anti-tumor effects in hepatoma cells. The me-
chanisms underlying bufalin action appear to mediate
the AKT/GSK3β/β-catenin/E-cadherin signaling path-
way. Bufalin is a promising anti-HCC agent, and further
studies should be performed in patients with HCC, espe-
cially those with advanced-stage disease.
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